Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Inflammatory Bowel Diseases Clinical Trial

Official title:

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03445624
• Other study ID #: assiut hospitals university
• Status: Completed
• Start date: July 1, 2018
• Est. completion date: October 1, 2021

Study information

• Verified date: July 2020
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Description:

the participants will follow up the patient for 1 year in the first visit

All patients in this study will be subjected to:

1. Detailed history.

2. Careful physical examination

3. laboratory investigation

1. complete blood picture.

2. liver function

3. kidney function

4. Iron profile(serum iron ,serum ferritin

5. ESR (erythrocyte sedimentation rate )

g-CRP (C reactive protein) f-LDH (lactate dehydrogenase)

4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs)

5. Doppler us (mesenteric vessels)

6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 1, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 60 Years

Eligibility

Inclusion Criteria

• patients diagnosed ulcerative colitis at age(15-60)

• patients diagnosed crohns disease at age(15-60)k

Exclusion criteria

• liver cirrhosis and portal hypertension

• spontaneous bacterial peritonitis

• Ischemic colitis

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Drug:
• Infliximab
follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy

Locations

Country	Name	City	State
Egypt	Hyam Fathy	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assesment inflammatory bowel disease by complete blood picture	follow up haemoglobin level (less than 10 mg) indicate anemia which mean the patient uncontrolled monocyte( monocyte more than 12% of white blood cell count detect activity) Mean platelet volume less than 6 fl which decrease in activity inflammatory bowel disease	2year
Primary	the role abdominal ultrasound in assessment inflammatory bowel disease	measure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity	2 year